Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer Summary Rechallenge with immune checkpoint inhibitors (ICIs) in advanced lung cancer patients who initially benefited but later progressed is a growing area of interest. Studies Read More